Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Myasthenia Gravis 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Oxaloacetic Acid × Clear all
NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Mayo Clinic

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT04965987 2025-07-11

Oxaloacetate in Myasthenia Gravis

University of Kansas Medical Center

Phase 1 Withdrawn

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡